The Definitive Peptide Research Reference Guide — Compound Review

Name: 5-Amino-1MQ Research Peptide
Brand: Purgo Labs
Price: 99.99 USD
Availability: InStock

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

5-Amino-1MQ Research Guide

5-Amino-1MQ — Nicotinamide N-Methyltransferase (NNMT) Inhibitor

Overview

5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in cellular methylation balance, NAD+ precursor availability, and adipose tissue metabolism. Unlike most compounds in the peptide research space, 5-Amino-1MQ is not a peptide — it is a quinolinium-based small molecule with a molecular weight of 174.20 Da. NNMT is overexpressed in white adipose tissue in obese individuals, where it consumes S-adenosylmethionine (SAM) — the body's primary methyl donor — to methylate nicotinamide, effectively draining the methyl pool and reducing NAD+ precursor availability. By selectively inhibiting NNMT, 5-Amino-1MQ preserves SAM and NAD+ precursors, creating a metabolic environment that favors fat oxidation over fat storage. In the pivotal 2018 animal study by Neelakantan et al., systemic treat

Mechanism of Action

5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that catalyzes the N-methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH) as products. In metabolically dysregulated adipose tissue, NNMT is overexpressed and consumes large quantities of SAM. This creates two downstream problems: (1) SAM depletion reduces the availability of methyl groups for other critical methylation reactions, including DNA and histone methylation; and (2) nicotinamide — a NAD+ precursor — is diverted away from the NAD+ synthesis pathway into the methylation pathway, reducing cellular NAD+ levels. By

Research Evidence

Reversed diet-induced obesity in mice within 11 days at 20 mg/kg without reducing food intake (Neelakantan et al., 2018)
Concentration-dependent NNMT inhibition in fully differentiated adipocytes confirmed in vitro (Neelakantan et al., 2018)
Combined with low-fat diet: dramatic whole-body adiposity reduction and metabolic normalization (Kannt et al., 2022)
Preserves NAD+ precursor availability and activates SIRT1-mediated fatty acid oxidation
High membrane permeability enables intracellular NNMT access without specialized delivery systems

Bottom line: 5-Amino-1MQ has a well-characterized molecular mechanism, strong animal study data, and a compelling differentiated profile versus GLP-1 agonists. No human clinical trials have been completed as of 2026. It remains a research compound with significant scientific interest.

Research Protocols & Dosage

Evidence-based research protocols, administration routes, and dosage considerations for 5-Amino-1MQ are detailed in the full compound profile. See also: Dosage guide for 5-Amino-1MQ.

Sourcing & Quality

5-Amino-1MQ is available from Purgo Labs with third-party COA verification and research-grade purity standards. View 5-Amino-1MQ at Purgo Labs.